Literature DB >> 11602091

[Safety in melatonin use].

A L Morera1, M Henry, M de La Varga.   

Abstract

INTRODUCTION: The interest on melatonin (MLT) as a psychiatric treatment has increased a lot in the last decade. This is mainly due to MLT safety and its lack of serious adverse reactions. The aim of this paper consists of reviewing the adverse effects to MLT consumption in humans.
METHOD: A 35-year (1966-2000) bibliographic search using the Medline database was carried out. The intersection of the key word melatonin with the group of words adverse effects or side effects or adverse reactions or toxicity was the strategy of the search.
RESULTS: 307 articles were elicited and 9 were related to MLT adverse effects. The range of MLT dose involved in the adverse reactions oscillated between 1 mg and 36 mg. The adverse reactions were: one patient with autoimmune hepatitis, one case of confusion due to MLT overdose, one case of optic neuropathy, four subjects with fragmented sleep, one psychotic episode, one case of nistagmus, four cases of seizures, one case of headache and two cases of skin eruptions.
CONCLUSIONS: Attention should be paid on the necessity of enquiring about the drugs that patients are taking, because this product is not harmless for health.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11602091

Source DB:  PubMed          Journal:  Actas Esp Psiquiatr        ISSN: 1139-9287            Impact factor:   1.196


  3 in total

Review 1.  Promising Role of Melatonin as Neuroprotectant in Neurodegenerative Pathology.

Authors:  Neeraj Joshi; Joyshree Biswas; C Nath; Sarika Singh
Journal:  Mol Neurobiol       Date:  2014-08-27       Impact factor: 5.590

2.  A randomized controlled trial of oral melatonin supplementation and breast cancer biomarkers.

Authors:  E S Schernhammer; A Giobbie-Hurder; K Gantman; J Savoie; R Scheib; L M Parker; W Y Chen
Journal:  Cancer Causes Control       Date:  2012-02-28       Impact factor: 2.506

Review 3.  Role of melatonin in schizophrenia.

Authors:  Armando L Morera-Fumero; Pedro Abreu-Gonzalez
Journal:  Int J Mol Sci       Date:  2013-04-25       Impact factor: 5.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.